Indian drugmakers expect a slowdown in new generic drug approvals by the US Food and Drug Administration (FDA) to weigh on sales in their largest market for at least two more quarters, due to an......
All generic drug makers, including Ranbaxy Laboratories, Cipla, Dr Reddy's Laboratories and Lupin, are now required to pay a fee to the US drug regulator while seeking permission to launch their......